Northwest Biotherapeutics (NWBO)

Northwest Biotherapeutics (NWBO) Financial Statements


Northwest Biotherapeutics Financial Overview

Northwest Biotherapeutics's market cap is currently ―. The company's EPS TTM is $-0.063; its P/E ratio is -6.14; Northwest Biotherapeutics is scheduled to report earnings on May 16, 2018, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 284.00K$ 445.00K$ 406.00K$ 201.00K$ 36.00K
Gross Profit$ 284.00K$ 445.00K$ 406.00K$ 201.00K$ 36.00K
EBIT$ -18.46M$ -17.68M$ -16.91M$ -13.15M$ -9.63M
EBITDA$ -17.38M$ -17.46M$ -16.42M$ -12.66M$ -9.29M
Net Income Common Stockholders$ -18.88M$ -19.26M$ -19.10M$ -13.93M$ -11.05M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 2.48M$ 2.13M$ 6.10M$ 1.42M$ 6.19M
Total Assets$ 28.57M$ 27.86M$ 31.49M$ 28.44M$ 32.87M
Total Debt$ 32.58M$ 32.79M$ 27.19M$ 30.76M$ 31.36M
Net Debt$ 30.10M$ 30.66M$ 21.09M$ 29.33M$ 25.17M
Total Liabilities$ 82.04M$ 74.92M$ 68.94M$ 89.47M$ 65.10M
Stockholders Equity$ -73.28M$ -65.77M$ -65.12M$ -61.03M$ -55.98M
Cash Flow-
Free Cash Flow$ -12.64M$ -17.38M$ -14.36M$ -12.77M$ -12.57M
Operating Cash Flow$ -12.41M$ -16.96M$ -13.92M$ -11.52M$ -11.24M
Investing Cash Flow$ -239.00K$ -418.00K$ -437.00K$ -1.25M$ -1.33M
Financing Cash Flow$ 12.09M$ 14.41M$ 17.12M$ 8.64M$ 12.58M
Currency in USD

Northwest Biotherapeutics Earnings and Revenue History

Northwest Biotherapeutics Debt to Assets

Northwest Biotherapeutics Cash Flow

Northwest Biotherapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis